Literature DB >> 8116039

Monotherapy with cyclosporine for chronic immunosuppression in pediatric liver transplant recipients.

S P Dunn1, K Falkenstein, J P Lawrence, R Meyers, C D Vinocur, D F Billmire, W H Weintraub.   

Abstract

Children who survive liver transplantation (LT) suffer the adverse effects of life-long immunosuppression. In an attempt to minimize these effects, we have instituted a program of tapering immunosuppression, resulting in chronic monotherapy for children after LT. Seventy-three children ages 4 months to 19 years received LT between January 1987 and December 1992. Patient survival was 85% (62/73), with graft survival of 73%, at one year. Triple therapy with prednisone, cyclosporine, and azathioprine begun at transplant was tapered as follows: 1-2 mg/kg prednisone at discharge was reduced by .2 mg/kg every 2 months until a .2 mg/kg total was reached. Alternate-day steroids (.2 mg/kg) were begun at 1 year and discontinued at 1.5 years. AZA (1 mg/kg) was begun posttransplant and discontinued after any serious viral illness or by 1 year. Currently 37 survivors are > 18 months post-LT and were considered candidates for monotherapy. Monotherapy was attempted in 28 (76%), and 25 of these remain on monotherapy an average of 2 years later. All have normal liver function. After monotherapy and alternate-day steroids were achieved, 66% of children < 5th percentile for height at the time of transplant improved to greater than the 5th percentile. There were 3 (11%) patients who rejected while on monotherapy an average of 1.15 years after it was started. These patients had the following predisposing factors that decreased cyclosporine levels and led to rejection: common bile duct stricture, chronic and intermittent antibiotic administration for urinary tract infection, and noncompliance. In the 9 potential candidates not tapered to monotherapy, 6 have had recurrent acute or chronic rejection; 2 of these now receive FK506. We conclude that the majority of stable pediatric LT recipients may be safely tapered to chronic cyclosporine monotherapy. Increased growth is a major benefit of decreased steroid dosing in these children. Cyclosporine absorption and adequate levels are crucial for success of this approach.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8116039

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  4 in total

Review 1.  Post-transplant hyperlipidaemia.

Authors:  R M Jindal
Journal:  Postgrad Med J       Date:  1997-12       Impact factor: 2.401

Review 2.  Efficacy of immunosuppression monotherapy after liver transplantation: a meta-analysis.

Authors:  Xiang Lan; Meng-Gang Liu; Hong-Xu Chen; Hong-Ming Liu; Wei Zeng; Dong Wei; Ping Chen
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 3.  Immunosuppressive drugs in paediatric liver transplantation.

Authors:  I D van Mourik; D A Kelly
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 4.  Pediatric liver transplantation.

Authors:  Marco Spada; Silvia Riva; Giuseppe Maggiore; Davide Cintorino; Bruno Gridelli
Journal:  World J Gastroenterol       Date:  2009-02-14       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.